AstraZeneca and MSD said that Lynparza (olaparib) in combination with standard-of-care (SoC) bevacizumab succeeded in a phase 3 trial in advanced ovarian cancer by meeting the primary endpoint.
Eli Lilly and Company (NYSE: LLY) announced today Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced initiation of the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.
AstraZeneca’s Tagrisso (osimertinib) has significantly improved overall survival (OS) in the patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer in the phase III Flaura trial.
Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicinium for the potential treatment of patients with high-risk, bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
AstraZeneca and MSD (known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).
HCL Technologies (HCL), a global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences today announced a collaboration to help life sciences companies execute and scale the next generation of digital clinical trials to reduce the time and cost of drug development.
Eli Lilly announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous failures on two to four different standard-of-care migraine preventive medication categories, due to inadequate efficacy or for safety/tolerability reasons.
Roche has announced that its Tecentriq (atezolizumab) plus platinum-based chemotherapy has significantly reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer in the phase III IMvigor130 study.
Transgene, a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, announces that the independent Data Monitoring Committee (IDMC) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.